Evidence map›Paper›PMID 39779678›Full record

ArticleCell death & disease2025

Aurora B inhibition induces hyper-polyploidy and loss of long-term proliferative potential in RB and p53 defective cells.

Shivam Vora, Saptarshi Chatterjee, Ariel Andrew, Ramyashree Prasanna Kumar, Martina Proctor, Zhen Zeng, Rituparna Bhatt, Deborah Nazareth, Madushan Fernando, Mathew J K Jones and 9 more

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Shivam VoraMater Research Institute, The University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0002-8256-3215
Saptarshi ChatterjeeDepartment of Biological Sciences and Fralin Life Sciences Institute, Virginia Tech, Blacksburg, USA.
Ariel AndrewMater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
Ramyashree Prasanna KumarMater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
Martina ProctorMater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
Zhen ZengMater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
Rituparna BhattMater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
Deborah NazarethMater Research Institute, The University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0002-5983-3571
Madushan FernandoMater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
Mathew J K JonesFrazer Institute, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0003-2714-8411
Yaowu HeMater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
John D HooperMater Research Institute, The University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0003-1054-8486
Nigel A J McMillanMenzies Health Institute Queensland and School of Medical Science, Griffith University, Gold Coast, Australia.ORCID 0000-0002-9471-1406
Jelena UrosevicResearch and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
Jamal SaehResearch and Early Development, Oncology R&D, AstraZeneca, Waltham, USA.
Jon TraversResearch and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
Daniela CiminiDepartment of Biological Sciences and Fralin Life Sciences Institute, Virginia Tech, Blacksburg, USA.ORCID 0000-0002-4082-4894
Jing ChenDepartment of Biological Sciences and Fralin Life Sciences Institute, Virginia Tech, Blacksburg, USA.ORCID 0000-0001-6321-0505
Brian GabrielliMater Research Institute, The University of Queensland, Brisbane, QLD, Australia. brianG@uq.edu.au.ORCID 0000-0003-3933-1651

Funding

Mathematical modeling of spatiotemporal and mechanical processes in cellular functionsR35GM138370 · NIGMS · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Jing Chen · 2020 to 2026
$2.0M
Department of Health | National Health and Medical Research Council (NHMRC) APP1104186NIGMS NIH HHS R35 GM138370
6 · The paper itself

Abstract

Polyploidy is a common outcome of chemotherapies, but there is conflicting evidence as to whether polyploidy is an adverse, benign or even favourable outcome. We show Aurora B kinase inhibitors efficiently promote polyploidy in many cell types, resulting in the cell cycle exit in RB and p53 functional cells, but hyper-polyploidy in cells with loss of RB and p53 function. These hyper-polyploid cells (>8n DNA content) are viable but have lost long-term proliferative potential in vitro and fail to form tumours in vivo. Investigation of mitosis in these cells revealed high numbers of centrosomes that were capable of supporting functional mitotic spindle poles, but these failed to progress to anaphase/telophase structures even when AURKB inhibitor was removed after 2-3 days. However, when AURKB inhibitor was removed after 1 day and cells had failed a single cytokinesis to become tetraploid, they retained colony forming ability and long-term proliferative potential. Mathematical modelling of the potential for polyploid cells to produce viable daughter cells demonstrated that cells with >8n DNA and >4 functional spindle poles approach zero probability of a viable daughter, supporting our experimental observations. These findings demonstrate that tetraploidy is tolerated by tumour cells, but higher ploidy states are incompatible with long-term proliferative potential. Model for AURKBi driven hyper-polyploid cells formation and fate. Aurora B inhibitor (AURKBi) treatment of RB+p53 defective cells efficiently promotes failed cell division. One failed cell division produces three possible outcomes, continued proliferation of the tetraploid daughter, cell death, or if AURKBi is continued, high polyploid states. Once cell have failed cell division >twice and have >8n DNA content they will continue to undergo rounds of endomitosis even in the absence of AURKBi to either become viable hyper-polyploid or die. The hyper-polyploid cells have no long-term proliferative potential.

Indexed as

Aurora Kinase BCell ProliferationPolyploidyTumor Suppressor Protein p53AnimalsCell Line, TumorHumansMiceMitosisProtein Kinase InhibitorsAURKB protein, humanAurora Kinase BProtein Kinase InhibitorsTumor Suppressor Protein p53

Identifiers

PMID39779678
PMCPMC11711630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.